Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
Leore T. GellerDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, IsraelMichal Barzily-RokniBroad Institute of MIT and Harvard, Cambridge, MA 02142, USATal DaninoInstitute for Medical Engineering and Science, Massachusetts Institute of Technology (MIT), Cambridge, MA 02139, USAOliver JonasDepartment of Radiology, Brigham and Women’s Hospital, Boston, MA 02115, USANoam ShentalDepartment of Mathematics and Computer Science, Open University of Israel, Raanana, IsraelDeborah NejmanDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, IsraelNancy GavertDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, IsraelYaara ZwangDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, IsraelZachary A. CooperDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAKevin SheeBroad Institute of MIT and Harvard, Cambridge, MA 02142, USAChristoph A. ThaissDepartment of Immunology, Weizmann Institute of Science, Rehovot, IsraelAlexandre ReubenDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAJonathan LivnyBroad Institute of MIT and Harvard, Cambridge, MA 02142, USARoi AvrahamDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, IsraelDennie T. FrederickDepartment of Surgical Oncology, Massachusetts General Hospital, Boston, MA 02114, USAMatteo LigorioMassachusetts General Hospital Cancer Center, Boston, MA 02114, USAKelly ChatmanSmall Molecule Mass Spectrometry Facility, Faculty of Arts and Sciences Division of Science, Harvard University, Cambridge, MA 02138, USAStephen JohnstonBroad Institute of MIT and Harvard, Cambridge, MA 02142, USACarrie M. MosherBroad Institute of MIT and Harvard, Cambridge, MA 02142, USAAlexander BrandisLife Sciences Core Facilities, Weizmann Institute of Science, Rehovot, IsraelGarold FuksDepartment of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, IsraelCandice R. GurbatriDepartment of Biomedical Engineering, Columbia University, New York City, NY 10027, USAVancheswaran GopalakrishnanDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAMichael P. KimDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAMark W. HurdAhmed Center for Pancreatic Cancer Research, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAMatthew H. G. KatzDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAJason B. FlemingDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAAnirban MaitraDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADavid A. SmithBroad Institute of MIT and Harvard, Cambridge, MA 02142, USAMatt SkalakInstitute for Medical Engineering and Science, Massachusetts Institute of Technology (MIT), Cambridge, MA 02139, USAJeffrey BuInstitute for Medical Engineering and Science, Massachusetts Institute of Technology (MIT), Cambridge, MA 02139, USAMonia MichaudHarvard T. H. Chan School of Public Health, Departments of Immunology and Infectious Diseases and Genetics and Complex Diseases, Boston, MA 02115, USASunia A. TraugerSmall Molecule Mass Spectrometry Facility, Faculty of Arts and Sciences Division of Science, Harvard University, Cambridge, MA 02138, USAIris BarshackDepartment of Pathology, Sheba Medical Center, Ramat Gan, IsraelTalia GolanDepartment of Oncology, Sheba Medical Center, Ramat Gan, IsraelJudith SandbankSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelKeith T. FlahertyMassachusetts General Hospital Cancer Center, Boston, MA 02114, USAAnna MandinovaBroad Institute of MIT and Harvard, Cambridge, MA 02142, USAWendy S. GarrettBroad Institute of MIT and Harvard, Cambridge, MA 02142, USASarah P. ThayerDepartment of Surgery, University of Nebraska Medical Center, Omaha, NE 68198-6345, USACristina R. FerronePancreas and Biliary Surgery Program, Massachusetts General Hospital, Boston, MA 02114, USACurtis HuttenhowerBroad Institute of MIT and Harvard, Cambridge, MA 02142, USASangeeta N. BhatiaBroad Institute of MIT and Harvard, Cambridge, MA 02142, USADirk GeversBroad Institute of MIT and Harvard, Cambridge, MA 02142, USAJennifer A. WargoDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USATodd R. GolubDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USARavid StraussmanDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
2017en
ABI
Abstract
expression, and abrogated by cotreatment with the antibiotic ciprofloxacin. Gemcitabine is commonly used to treat pancreatic ductal adenocarcinoma (PDAC), and we hypothesized that intratumor bacteria might contribute to drug resistance of these tumors. Consistent with this possibility, we found that of the 113 human PDACs that were tested, 86 (76%) were positive for bacteria, mainly Gammaproteobacteria.
Identifiers
Citations and references
Cited by 20 references